carnitine has been researched along with Chronic Hepatitis B in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n=31), 150 mg (n=28) and entecavir 0." | 9.20 | Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. ( Ahn, SH; Cho, M; Han, KH; Kim, JA; Kweon, YO; Lai, CL; Lee, J; Lee, JW; Lee, KS; Park, NH; Sohn, JH; Um, SH; Yoon, SK; Yuen, MF, 2015) |
| " The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients." | 9.17 | Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. ( Bae, SH; Baek, YH; Cheong, JY; Cho, SW; Cho, YK; Choi, JY; Han, SY; Heo, J; Hwang, SG; Jun, DW; Jung, YJ; Kim, BI; Kim, HJ; Kim, HY; Kim, JK; Kim, SH; Kim, TY; Kim, W; Kwon, YO; Lee, BS; Lee, KS; Lee, YS; Lim, YS; Paik, YH; Park, SY; Rim, KS; Sohn, JH; Woo, HY, 2013) |
| "The outcome of hepatitis B virus (HBV) infection is significantly affected by host immune response; herein, we aim to dissect the effect of L-carnitine (L-Cn) on germinal center (GC)-related immune cells and the influence on the prognosis of HBV infection." | 8.12 | Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells. ( Chen, C; Fu, X; Gu, S; Guo, L; Hou, J; Li, X; Li, Y; Sun, J; Tang, L; Wang, W; Wen, C; Ye, G; Zhong, S; Zhou, Y, 2022) |
| "Carnitine status of children with chronic hepatitis B is not yet clear." | 7.72 | Plasma and liver carnitine levels of children with chronic hepatitis B. ( Selimoğlu, MA; Yağci, RV, 2004) |
| "Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control." | 5.62 | High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. ( Chen, C; Chen, H; Fu, X; Gu, S; Hou, J; Jiang, D; Li, X; Li, Y; Tang, L; Ye, G; Zhong, S, 2021) |
| "Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n=31), 150 mg (n=28) and entecavir 0." | 5.20 | Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. ( Ahn, SH; Cho, M; Han, KH; Kim, JA; Kweon, YO; Lai, CL; Lee, J; Lee, JW; Lee, KS; Park, NH; Sohn, JH; Um, SH; Yoon, SK; Yuen, MF, 2015) |
| " The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients." | 5.17 | Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. ( Bae, SH; Baek, YH; Cheong, JY; Cho, SW; Cho, YK; Choi, JY; Han, SY; Heo, J; Hwang, SG; Jun, DW; Jung, YJ; Kim, BI; Kim, HJ; Kim, HY; Kim, JK; Kim, SH; Kim, TY; Kim, W; Kwon, YO; Lee, BS; Lee, KS; Lee, YS; Lim, YS; Paik, YH; Park, SY; Rim, KS; Sohn, JH; Woo, HY, 2013) |
| "The outcome of hepatitis B virus (HBV) infection is significantly affected by host immune response; herein, we aim to dissect the effect of L-carnitine (L-Cn) on germinal center (GC)-related immune cells and the influence on the prognosis of HBV infection." | 4.12 | Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells. ( Chen, C; Fu, X; Gu, S; Guo, L; Hou, J; Li, X; Li, Y; Sun, J; Tang, L; Wang, W; Wen, C; Ye, G; Zhong, S; Zhou, Y, 2022) |
| "In chronic hepatitis B patients treated with peginterferon and adefovir, we identified strong associations of SLC16A9 gene variation and carnitine levels with HBsAg loss." | 3.80 | HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. ( Chin, DJ; de Niet, A; Jansen, L; Kootstra, NA; Lopatin, U; Plat-Sinnige, MJ; Reesink, HW; Stelma, F; Takkenberg, RB; van Dort, KA; van Iperen, EP; Zwinderman, AH, 2014) |
| "Carnitine status of children with chronic hepatitis B is not yet clear." | 3.72 | Plasma and liver carnitine levels of children with chronic hepatitis B. ( Selimoğlu, MA; Yağci, RV, 2004) |
| "Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control." | 1.62 | High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. ( Chen, C; Chen, H; Fu, X; Gu, S; Hou, J; Jiang, D; Li, X; Li, Y; Tang, L; Ye, G; Zhong, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, S | 2 |
| Wang, W | 1 |
| Ye, G | 2 |
| Chen, C | 2 |
| Zhou, Y | 1 |
| Guo, L | 1 |
| Zhong, S | 2 |
| Li, X | 2 |
| Fu, X | 2 |
| Wen, C | 1 |
| Tang, L | 2 |
| Sun, J | 1 |
| Hou, J | 2 |
| Li, Y | 2 |
| Chen, H | 1 |
| Jiang, D | 1 |
| Jun, DW | 1 |
| Kim, BI | 1 |
| Cho, YK | 1 |
| Kim, HJ | 1 |
| Kwon, YO | 1 |
| Park, SY | 1 |
| Han, SY | 1 |
| Baek, YH | 1 |
| Jung, YJ | 1 |
| Kim, HY | 1 |
| Kim, W | 1 |
| Heo, J | 1 |
| Woo, HY | 1 |
| Hwang, SG | 1 |
| Rim, KS | 1 |
| Choi, JY | 1 |
| Bae, SH | 1 |
| Lee, YS | 1 |
| Lim, YS | 1 |
| Cheong, JY | 1 |
| Cho, SW | 1 |
| Lee, BS | 1 |
| Kim, SH | 1 |
| Sohn, JH | 3 |
| Kim, TY | 1 |
| Paik, YH | 1 |
| Kim, JK | 1 |
| Lee, KS | 3 |
| Lai, CL | 2 |
| Ahn, SH | 2 |
| Um, SH | 2 |
| Cho, M | 2 |
| Yoon, SK | 2 |
| Lee, JW | 2 |
| Park, NH | 2 |
| Kweon, YO | 2 |
| Lee, J | 2 |
| Kim, JA | 2 |
| Han, KH | 2 |
| Yuen, MF | 2 |
| Jansen, L | 1 |
| de Niet, A | 1 |
| Stelma, F | 1 |
| van Iperen, EP | 1 |
| van Dort, KA | 1 |
| Plat-Sinnige, MJ | 1 |
| Takkenberg, RB | 1 |
| Chin, DJ | 1 |
| Zwinderman, AH | 1 |
| Lopatin, U | 1 |
| Kootstra, NA | 1 |
| Reesink, HW | 1 |
| Selimoğlu, MA | 1 |
| Yağci, RV | 1 |
| Eskandari, GH | 1 |
| Polat, G | 1 |
| Tamer, L | 1 |
| Ersöz, G | 1 |
| Atik, U | 1 |
3 trials available for carnitine and Chronic Hepatitis B
| Article | Year |
|---|---|
Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carnitine; DNA, Viral; Drug Therapy, Combination; Enz | 2013 |
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Asian People; Carnitine; DNA, Vira | 2014 |
Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carnitine; DNA, Viral; Female; Guanine; Hepatitis B e | 2015 |
5 other studies available for carnitine and Chronic Hepatitis B
| Article | Year |
|---|---|
Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells.
Topics: Animals; Carnitine; Germinal Center; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; H | 2022 |
High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase; CD4 | 2021 |
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Topics: Adenine; Adult; Antiviral Agents; Carnitine; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; | 2014 |
Plasma and liver carnitine levels of children with chronic hepatitis B.
Topics: Adolescent; Antiviral Agents; Carnitine; Child; Child, Preschool; Drug Therapy, Combination; Female; | 2004 |
Serum L-carnitine levels and lipoprotein compositions in chronic viral hepatitis patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Choles | 2001 |